To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The effect of LongoVital … - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial.

Journal article
Authors John Bratel
Magnus Hakeberg
Mats Jontell
Published in Oral health & preventive dentistry
Volume 3
Issue 1
Pages 3-8
ISSN 1602-1622
Publication year 2005
Published at Institute of Odontology
Pages 3-8
Language en
Links www.ncbi.nlm.nih.gov/entrez/query.f...
Keywords Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Phytotherapy, Plant Components, Plant Preparations, therapeutic use, Plants, Medicinal, Recurrence, prevention & control, Statistics, Nonparametric, Stomatitis, Aphthous, prevention & control, Tablets, Vitamins, therapeutic use
Subject categories Dentistry, Other odontology

Abstract

PURPOSE: The aim of this study was to evaluate the effect of daily intake of LongoVital (LV) (herbal vitamin tablets) in the prevention of RAS. MATERIALS AND METHODS: A group of 78 consecutively referred patients was enrolled to a three-months pretreatment period. Fifty subjects were then randomly allocated to an LV-group (n = 25) or a placebo group (N = 25). A double blind, stratified-randomised clinical case-control study was performed during six months. Number and size of the ulcers were registered by the patients using a standardized chart. The degree of discomfort was recorded on a 100 mm horizontal visual analogue scale (VAS-scale). RESULTS: The three-months pretreatment period revealed that the most dominant symptoms were pain (78%) followed by burning sensation (18%). No significant differences between the two groups were found during this period when a comparison was made at the end of the study. After the intervention period the number of aphthous ulcers/month decreased significantly in the LV-group (p = 0.02). The number of days in pain/month were also reduced (p < 0.001). If a 50% reduction of number of aphthous ulcers and days in pain were considered as clinically relevant, no statistical significant differences were found between the groups. CONCLUSION: Thus, no strong evidence was found that justified a recommendation of LV as a general drug for treatment of RAS.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?